Contributor Page
Mintz
 
Email  |  Website  |  Articles
Contact Details
Tel: +1 617 5426000
Fax: +1 617 5422241
One Financial Center
Boston
MA 02111
United States
By Cynthia Larose
The California 2019 legislative session closes on Friday, and thus all bills must be finalized to move to the Governor's desk for signature. That means that all CCPA pending amendments
By Cynthia Larose
51 tech company CEOs today signed and sent an open letter to Congress asking for help to hold off and supersede the rising number of state privacy laws growing like weeds.
By Gilbert Samberg
Heads up, sureties! (And all other contracting parties.) Incorporation by reference of the terms of one agreement into another is a classical common law basis for binding
By Cynthia Larose
As we reported here, the final days of the 2019 California legislative session are winding down, with important amendments to the California Consumer Privacy Act (CCPA) still pending.
By Donald C. Davis
We know August was exhausting for employers – New York, New Jersey, Maine, Colorado, and yes, even Alabama
By Mintz Levin Immigration Group
According to U.S. Customs and Border Protection (CBP), the extended government shutdown earlier this year, as well as the ongoing crisis at the southern border with Mexico
By Timothy McKeon
On August 23, 2019, President Trump signed into law the "Small Business Reorganization Act of 2019."
By Dianne Bourque, Cassandra Paolillo
On August 22, the Substance Abuse and Mental Health Services Administration ("SAMHSA") announced a new proposed rule (the "Proposed Rule") amending 42 CFR part 2
By Gilbert Samberg
The United States joined 45 other countries on August 7, 2019 as the initial signatories of the UN Convention on International Settlement Agreements Resulting from Mediation
By Benjamin Zegarelli, Ellen Janos
On August 8, 2019, FDA issued a notice on its medical device recall database stating that a company called Opternative, Inc.
By Bridgette Keller
GAO recently released a report analyzing the use of pharmacy benefit managers ("PBMs") and efforts to manage drug spending and use in the Medicare Part D program
By Joanne Hawana, Elizabeth K. Conti
Looks like the Drug Pricing Disclosure Rule may not have seen its last day in court.
By Cynthia Larose, Elana Safner
They grow up so fast! A sentiment – and challenge – shared by parents and technologists alike. Just when you think you've finally figured it out, you blink, and they're unrecognizable.
By Rachel Pitts
Our ML Strategies colleague Aaron Josephson was quoted extensively in an August 16 FDA Week article (FDA Week is a focused newsletter from InsideHealthPolicy)
By Jane Haviland, Karen Lovitch
On August 20, 2019, the United States exercised its authority under the False Claims Act (FCA) to seek dismissal of a relator's qui tam suit because of the defendant's burdensome discovery
Contributor's Topics
More...